VJHemOnc

The Video Journal of Hematology & Hematological Oncology is dedicated to providing up-to-date information & international expertise

[VJHemOnc @VJHemOnc]

Do CTCs have a role as an independent prognostic factor in #multiplemyeloma? 🩸

Find out from Pieter Sonneveld of @ErasmusMC, who shared his insights in an interview at #IMS26:

👉 https://t.co/kh3YyHI9zh 👈

#Myeloma #MMsm @Myeloma_Society

[VJHemOnc @VJHemOnc]

In a recent interview at #SOHO2026, Amin Azem of @MoffittNews shared insights into the potential of moving towards chemo-free, TKI-sparing strategies in Ph+ acute lymphoblastic #leukemia.

Watch the full interview here:
➡️ https://t.co/eysJFi28r1

#Leusm #ALLsm #HemOnc

[VJHemOnc @VJHemOnc]

It was great to speak with @YiLinMDPhD of @MayoCancerCare at #IMS26!

She discussed immune fitness and reconstitution in #multiplemyeloma following #CART and T-cell engager therapy. To watch her full video interview, click here:

👉 https://t.co/rb7lraWuwf 👈

#MMsm #Myeloma #ImmunoOnc @Myeloma_Society

[VJHemOnc @VJHemOnc]

How is the treatment landscape for essential thrombocythemia evolving? 🧬🩸

In this exclusive interview, @AaronGerds of @ClevelandClinic shares expert insight on emerging therapies and molecular advances in ET:

🎥 https://t.co/GhcEGTNddg

#MPNsm #HemOnc #Hematology #SOHO2026

[VJHemOnc @VJHemOnc]

🎥 Iskra Pusic of @WashUDeptMed recently discussed major breakthroughs in #leukemia treatment. To discover more about the shift from conventional chemotherapy to precision therapies, click here:

👉 https://t.co/XCniHhig4U 👈

#Leusm #ImmunoOnc #HemOnc #SOHO2026 @SocietyofHemOnc

[VJHemOnc @VJHemOnc]

Want to hear insights into transplant decision-making in T-cell #lymphoma? 🩸

At #SOHO2026, @MaryjoLechowicz of @WinshipAtEmory provided valuable advice on deciding between autoSCT and alloSCT.

Watch her full interview here:
🎥 https://t.co/vUyn2WLfvZ

#BMTsm #LYMsm #NonHodgkinLymphoma

[VJHemOnc @VJHemOnc]

At #IMS26, @MyMKaiser of @royalmarsdenNHS discussed genetic risk factors in ultra-high-risk #multiplemyeloma. 🧬

To learn more, click here:
👉 https://t.co/FFnzqnnqE7

#Myeloma #MMsm #CaGenome

[VJHemOnc @VJHemOnc]

🎙️ New VJHemOnc Podcast | Multiple Myeloma Updates from IMS 2026

From long-term PERSEUS outcomes and sustained MRD negativity to MajesTEC-3, cilta-cel and novel agents, hear leading experts discuss advances shaping multiple myeloma treatment.

🎧 Listen now: https://t.co/9GpLYdADuN

@Myeloma_Society #MMSM #Myeloma #MultipleMyeloma #CTSM #TrialUpdate #ImmunoOnc #CART #HemOnc

[VJHemOnc @VJHemOnc]

New insights from the Phase III SENTRY trial! 🚨

In a recent interview, @bose_prithviraj of @UTMDAnderson shared updates from the study evaluating selinexor plus ruxolitinib in JAK inhibitor-naive #myelofibrosis.

Click here to watch:
🎥 ➡️ https://t.co/qi2UhCpKDL

#MPNsm #TrialUpdate #CTSM #HemOnc #SOHO2026

[VJHemOnc @VJHemOnc]

One week to go until the 2026 ERIC International Meeting! 🇪🇸🚨

This time next week, we'll be heading to Barcelona to catch the latest in CLL from the field's leading experts.

🔗 🎥 Follow along for exclusive expert interviews on https://t.co/Vqyt4af67F.

#CLLsm #Leukemia #Leusm #HemOnc #Hematology

[VJHemOnc @VJHemOnc]

Want to hear about emerging approaches for AL #amyloidosis? 🩸

@Ron_Witteles of @StanfordDeptMed discussed this at #ESCCongress. Click here for his expert insights:

🎥 https://t.co/2G2hnyDKhe

@escardio #HemOnc #Hematology #CardioOnc

[VJHemOnc @VJHemOnc]

What are myeloma experts talking about right now? 📣🩸

We asked them at #IMS26, and the conversations covered everything from emerging treatments to the data shaping clinical practice today.

Watch our exclusive interviews for key insights from the meeting here:

👉 https://t.co/e8HXM9buCX 👈

#MMsm #Myeloma #HemOnc @Myeloma_Society

[VJHemOnc @VJHemOnc]

The MYELOMAS 2nd International Meeting will be taking place from October 22–24, 2026, in Rome, Italy.🇮🇹

This event will bring together international & Italian experts to discuss the present and future of #myeloma management, covering topics such as MRD, disease biology, novel therapies, frontline and relapsed treatment strategies, and personalized medicine.🩺🩸

Click here to view the program & register:
👉 https://t.co/9n3dT2kB8j 👈

#MultipleMyeloma #MMSM #HemOnc @DottorClaudio

[VJHemOnc @VJHemOnc]

At #SOHO2026, @jorgecortesmd of @uabmedicine shed light on a key unresolved question in chronic myeloid #leukemia: how to manage patients with additional genetic abnormalities at diagnosis. 🧬

Watch here:
🎥 👉 https://t.co/WoFDzONvzy

#CMLsm #Leusm #CaGenome

[VJHemOnc @VJHemOnc]

The concept of cure in #multiplemyeloma was a key topic of discussion at #IMS26.

It was lovely to speak with @AhlstromJenny of @HealthTree at the meeting and hear her thoughts on this concept from a patient's perspective.

Watch the full interview here:
🎥 https://t.co/1TUfSxgywk

#MMsm #Myeloma @Myeloma_Society

[VJHemOnc @VJHemOnc]

In a recent interview, Simona Soverini of @Unibo discussed challenges in assessing treatment resistance and loss of response in chronic myeloid #leukemia. 🩸

Watch here:
🎥 👉 https://t.co/2y2sEmbTa6

#CMLsm #Leusm #HemOnc #SOHO2026

[VJHemOnc @VJHemOnc]

🚨 Can mitapivat reshape everyday care in sickle cell disease?

With gene therapies offering potentially curative treatment for selected patients, oral disease-modifying therapies remain an important part of the SCD treatment landscape.

Our latest feature examines Phase III RISE UP data for mitapivat and what the findings could mean for future SCD care.

🗞️ Read more: https://t.co/KPP62qUSJI

#SCD #SickleCellDisease #SickleCell #CTSM #TrialUpdates #Mitapivat #HemOnc #Hematology

[VJHemOnc @VJHemOnc]

Missed out on #SOHO2026? We've got you covered.🚨

To watch top experts break down the latest #HemOnc updates, click here.👇

🎥 https://t.co/4BI9zWiqWc

#Hematology @SocietyofHemOnc

[VJHemOnc @VJHemOnc]

🎙️ BTK inhibitors in CLL: beyond treatment selection

Molecular risk, cardiovascular health, comorbidities and patient preferences can all influence treatment decisions.

Hear @KerryARogersMD Florian Simon, @DrDimaE and Gianluca Gaidano discuss how BTK inhibitor therapy can be personalized in #CLL.

🎧 https://t.co/atpoMShAl8

#CLLsm #BTKInhibitors #Leukemia

[VJHemOnc @VJHemOnc]

🧬 FDA approval in frontline chronic lymphocytic leukemia!

On October 2, 2026, the FDA approved pirtobrutinib for adults with previously untreated CLL.

Read our latest feature article for insights into the BRUIN CLL-313 trial data and the potential impact of this approval, including expert perspectives from Wojciech Jurczak.

🗞️ Click here: https://t.co/2808kSMuVb

#Leusm #CLLsm #HemOnc #CTSM